| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/09/2005 | US20050123559 Such as psoriasis; a natural leukotriene inhibitor such as Boswellia serrata gum resin, or boswellic acid or derivatives, and an organic nutritional selenium source such as selenomethionine; no negative side effects; oral or topical administration dosage forms |
| 06/09/2005 | US20050123557 AntiI-protozoal vaccine |
| 06/09/2005 | US20050123551 Nucleic acids encoding polypeptides present in normal and neoplastic endometrial cells for use in diagnosis and treatment of endometrial cancer, identifying endometrial tissue; vectors, host cells; vaccines against endometrial cancer |
| 06/09/2005 | US20050123550 Enhances the efficacy and protective immune response of the vaccine by specifically targeting the intradermal compartment of a subject's skin; an antigenic or immunogenic agent and a molecule that enhances the immune response e.g. gelling agent and bioadhesive; no booster shot required |
| 06/09/2005 | US20050123543 With an integrin linked kinase (ILK) inhibitor which can be a peptide, an antibody, an antisense agent; optionally also treating with an ACE inhibitor; ACE (Angiotensin Converting Enzyme) |
| 06/09/2005 | US20050123541 Anti-TNF antibodies, compositions, methods and uses |
| 06/09/2005 | US20050123536 Treatment of immunological disorders using anti-dc30 antibodies |
| 06/09/2005 | US20050123533 Prodrugs activated by targeted catalytic proteins |
| 06/09/2005 | US20050123523 Immunostimulatory nucleic acid molecules |
| 06/09/2005 | US20050123514 increasing the transfer of ATP-binding cassette (ABC) transporter expressing cells with retroviral vectors, by contacting with verapamil, diltiazem, quinidine, ritonavir and lentiviruses |
| 06/09/2005 | US20050123512 Binding agents, vectors, host cells; gene therapy; nucleotide sequence with DNA insert encoding polypeptide; genetic engineering; medical diagnosis |
| 06/09/2005 | US20050123509 Modulating charge density to produce improvements in the characteristics of spray-dried proteins |
| 06/09/2005 | US20050123506 Administering a NF- kappa B inhibitor in conjunction with the administration of a chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased |
| 06/09/2005 | US20050123504 Based on kinetics; quality control kits |
| 06/09/2005 | US20050123502 Nicotine containing oral compositions |
| 06/09/2005 | US20050123491 Composition and method for treating onychomycosis |
| 06/09/2005 | US20050123489 Medicated chewing gum delivery system for nicotine |
| 06/09/2005 | US20050123486 inhalers used in the treatment of respiratory system disorders, such as chronic obstructive pulmonary disease and asthma |
| 06/09/2005 | US20050123484 comprising a concentrate of a local anesthetic in a non-alcohol solvent and a hydrofluorocarbon propellant, used for for accurate metered dose delivery |
| 06/09/2005 | US20050123481 Radio-opaque polymeric biomaterials |
| 06/09/2005 | US20050121667 Method of doping organic semiconductors with quinonediimine derivatives |
| 06/09/2005 | US20050121032 Pre-metered dry powder inhaler for moisture-sensitive medicaments |
| 06/09/2005 | US20050121027 Inhalable tiotropium and container therefor |
| 06/09/2005 | US20050121026 Method for administration of tiotropium |
| 06/09/2005 | DE68918191C5 Verfahren zur Lactonisierung von Mevinsäuren und deren Analogen. A method for lactonization of Mevinsäuren and their analogs. |
| 06/09/2005 | DE10352499A1 Substituierte Dihydrochinazoline II Substituted dihydroquinazolines II |
| 06/09/2005 | DE10352369A1 Verwendung von Licocalchon A oder eines Licocalchon A enthaltenden Extraktes aus Radix Glycyrrhizae inflatae gegen postinflammatorische Hyperpigmentierung Use of licochalcone A or A licochalcone containing extract of Radix Glycyrrhizae inflatae postinflammatory hyperpigmentation against |
| 06/09/2005 | DE10352368A1 Treatment of insect bites using licochalcone A or extracts of Radix Glycyrrhizae inflatae, provides long-lasting suppression of redness, itching and swelling |
| 06/09/2005 | DE10352367A1 Treatment of rosacea using licochalcone A or extracts of Radix Glycyrrhizae inflatae, provides long-lasting suppression of redness and inhibits further outbreaks |
| 06/09/2005 | DE10352132A1 Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten A pharmaceutical composition of a beta-3-adrenoceptor agonist and an alpha agonists |
| 06/09/2005 | DE10352131A1 Composition, useful to treat e.g. a morbid change to or an irritation of the prostate, comprises a first active agent (alpha antagonists or 5-alpha reductase inhibitors) and a second active agent (beta-3-adrenoceptor agonists) |
| 06/09/2005 | DE10351903A1 Neue Kombination New combination |
| 06/09/2005 | DE10351448A1 Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften Flavor-containing drug formulations with improved pharmaceutical properties |
| 06/09/2005 | DE10351436A1 Verwendung von Thienopyrimidinen Use of Thienopyrimidinen |
| 06/09/2005 | DE10350528A1 Arzneimittelformulierung, enthaltend einen LTB4-Antagonisten, sowie Verfahren zu deren Herstellung und deren Verwendung Pharmaceutical formulation comprising a LTB4 antagonist, and methods for their preparation and their use |
| 06/09/2005 | DE10347824A1 Pharmazeutische oder kosmetische Zusammensetzung zur Behandlung der Haut A pharmaceutical or cosmetic composition for treating the skin |
| 06/09/2005 | DE10066022B4 Medicament useful for treating immunological disorders, Alzheimer's disease, diabetes and obesity comprises a nettle extract prepared using an extractant other than water, ethanol and their mixtures |
| 06/09/2005 | CA2814523A1 Colonic purgative composition with soluble binding agent |
| 06/09/2005 | CA2547972A1 Fused ring dicationic anti-protozoan agents and their prodrugs |
| 06/09/2005 | CA2547472A1 Cyclic amine derivative having heteroaryl ring |
| 06/09/2005 | CA2547467A1 Piperidine compound and method for producing same |
| 06/09/2005 | CA2547459A1 Modulators of nik-siva complex formation for treating immune disorders |
| 06/09/2005 | CA2547444A1 7-[4-(4-chlorobenzyloxy) benzenesulfonyl]-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1h-3-benzazepinium maleate or tosylate as antipsychotics |
| 06/09/2005 | CA2547430A1 Receptor function regulating agent |
| 06/09/2005 | CA2547427A1 Composition having liver function protective effect |
| 06/09/2005 | CA2547398A1 Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating |
| 06/09/2005 | CA2547326A1 Novel muscle growth regulator |
| 06/09/2005 | CA2547311A1 Novel analgesic compounds, extracts containing same and methods of preparation |
| 06/09/2005 | CA2547282A1 Nitroso derivatives of diphenylamine |
| 06/09/2005 | CA2547235A1 T-type calcium channel blocker |
| 06/09/2005 | CA2547146A1 Diphenylamine derivatives |
| 06/09/2005 | CA2547124A1 Tubular proteinuria as an indicator for elevated cardiovascular risk |
| 06/09/2005 | CA2547086A1 Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof |
| 06/09/2005 | CA2547085A1 Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| 06/09/2005 | CA2547053A1 Compositions and methods for treatment of cardiovascular disorders and diseases |
| 06/09/2005 | CA2547051A1 Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
| 06/09/2005 | CA2547020A1 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier |
| 06/09/2005 | CA2546932A1 Quinazolinone compounds as anticancer agents |
| 06/09/2005 | CA2546863A1 Chaperone-based therapy for niemann-pick disease |
| 06/09/2005 | CA2546861A1 Treatment of a condition in a mammal with administration of compounds and methods of use thereof |
| 06/09/2005 | CA2546754A1 Akt protein kinase inhibitors |
| 06/09/2005 | CA2546747A1 Ttbks as modifiers of the beta catenin pathway and methods of use |
| 06/09/2005 | CA2546740A1 Hyperbranched polymers |
| 06/09/2005 | CA2546709A1 Amino substituted pyridinyl methanone compounds useful in treating kinase disorders |
| 06/09/2005 | CA2546673A1 Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
| 06/09/2005 | CA2546672A1 Use of c-(2-phenyl-cyclohexyl)-methylamine compounds for the treatment of anxiety disorders |
| 06/09/2005 | CA2546664A1 Anti-igfr1 antibody therapeutic combinations |
| 06/09/2005 | CA2546637A1 Colonic purgative composition with soluble binding agent |
| 06/09/2005 | CA2546619A1 Il-23 and its receptor; related reagents and methods |
| 06/09/2005 | CA2546601A1 Novel phosphorus-containing thyromimetics |
| 06/09/2005 | CA2546583A1 Methods and formulations for the treatment of medical conditions related to elevated dihydrotestosterone |
| 06/09/2005 | CA2546493A1 Indazole compounds and methods of use thereof as protein kinase inhibitors |
| 06/09/2005 | CA2546486A1 Heterocyclic inhibitors of mek and methods of use thereof |
| 06/09/2005 | CA2546405A1 Peptidically buffered formulations for electrotransport applications and methods of making |
| 06/09/2005 | CA2546399A1 Methods for preparing polymeric buffer formulations for electrotransport applications |
| 06/09/2005 | CA2546395A1 Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors |
| 06/09/2005 | CA2546377A1 Method of purifying pravastatin |
| 06/09/2005 | CA2546366A1 Using of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dymethyl-pyridine-3,5-dicarboxylate in the treatment of memory disorders |
| 06/09/2005 | CA2546360A1 Methods of treating diseases and disorders by targeting multiple kinases |
| 06/09/2005 | CA2546353A1 Bicyclic inhibitors of mek and methods of use thereof |
| 06/09/2005 | CA2546347A1 Methods and reagents for the treatment of inflammatory disorders |
| 06/09/2005 | CA2546318A1 Pyrrolo-pyrazine derivatives useful as cb1-modulators |
| 06/09/2005 | CA2546290A1 Depeptidized inhibitors of hepatitis c virus ns3 protease |
| 06/09/2005 | CA2546280A1 Composition and apparatus for transdermal delivery |
| 06/09/2005 | CA2546264A1 4-phenylpiperidine derivatives as renin inhibitors |
| 06/09/2005 | CA2546248A1 Phosphodiesterase v inhibitor formulations |
| 06/09/2005 | CA2546244A1 Compositions comprising organic compounds |
| 06/09/2005 | CA2546142A1 Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease |
| 06/09/2005 | CA2546116A1 Estrogen receptor modulators |
| 06/09/2005 | CA2546042A1 Amelioration of macular degeneration and other ophthalmic diseases |
| 06/09/2005 | CA2545823A1 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof |
| 06/09/2005 | CA2545786A1 Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain |
| 06/09/2005 | CA2545660A1 Heterocyclic inhibitors of mek and methods of use thereof |
| 06/09/2005 | CA2545659A1 Bicyclic inhibitors of mek |
| 06/09/2005 | CA2545655A1 Combination drug therapy to treat obesity |
| 06/09/2005 | CA2545601A1 Quinazolinone compounds with reduced bioaccumulation |
| 06/09/2005 | CA2545572A1 Compositions of oligosaccharides for reducing pathogenic bacteria in the gastrointestinal tract of companion animals |
| 06/09/2005 | CA2545559A1 Method of decreasing fat deposits and body weight in mammals and birds |
| 06/09/2005 | CA2545545A1 Particle-forming compositions containing fused pyrrolocarbazoles |
| 06/09/2005 | CA2545478A1 Indolyl-thieno'3,4-bipyrazin-3-one derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |